FDA-cleared profile

TeraRecon Aorta.CT (1.1.0)

TeraRecon, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: TeraRecon Aorta.CT (1.1.0) automatically segments the aorta and labels 22 aortic anatomical landmarks from adult contrast CTA DICOM for trained professionals' review in standard-of-care planning; it does not alter the original images or provide a diagnosis and excludes the FDA-listed device/anatomy conditions.

Clinical role
Automatic aortic segmentation and landmarking to support clinician measurements and procedure planning; the qualified professional remains responsible for interpretation and patient management.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The indication is for adults and excludes patients with a pre-existing aortic device, bicuspid aortic valve anomaly, aortic dissection, aortic rupture, or abdominal metallic devices. Motion, occluded vessels, lack of contrast, artifacts, or landmarks outside the field of view can prevent annotation or affect output. The device does not alter original input data and does not provide a diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: TeraRecon Aorta.CT (1.1.0) automatically segments the aorta and labels 22 aortic anatomical landmarks from adult contrast CTA DICOM for trained professionals' review in standard-of-care planning; it does not alter the original images or provide a diagnosis and excludes the FDA-listed device/anatomy conditions.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Contrast CT angiography DICOM images of the adult cardiac and/or abdominal aorta.
  • Who uses it?Intended users: Trained professionals responsible for patient management; results are used with other patient information and the standard of care.
  • What does the software produce?Output: Automatic 3D aortic lumen and wall-to-wall segmentation with 22 labeled aortic anatomical landmarks, delivered as DICOM result files viewable by DICOM-compliant systems.
  • What is its most important limitation?Key limitation: The indication is for adults and excludes patients with a pre-existing aortic device, bicuspid aortic valve anomaly, aortic dissection, aortic rupture, or abdominal metallic devices. Motion, occluded vessels, lack of contrast, artifacts, or landmarks outside the field of view can prevent annotation or affect output. The device does not alter original input data and does not provide a diagnosis.

Clinical takeaway. Clinical role: TeraRecon Aorta.CT (1.1.0) automatically segments the aorta and labels 22 aortic anatomical landmarks from adult contrast CTA DICOM for trained professionals' review in standard-of-care planning; it does not alter the original images or provide a diagnosis and excludes the FDA-listed device/anatomy conditions.

Evidence takeaway. Evidence from the reviewed source record: K243158 FDA evidence is a retrospective manufacturer-submitted regulatory validation. Segmentation results come from 170 adult aortic CTA studies; landmarking required 29 supplemental studies after field-of-view and artifact exclusions, so the exact unique total across endpoints is not inferred. No independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
TeraRecon Aorta.CT (1.1.0) automatically segments the aorta and labels 22 aortic anatomical landmarks from adult contrast CTA DICOM for trained professionals' review in standard-of-care planning; it does not alter the original images or provide a diagnosis and excludes the FDA-listed device/anatomy conditions.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Automatic aortic segmentation and landmarking to support clinician measurements and procedure planning; the qualified professional remains responsible for interpretation and patient management.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Contrast CT angiography DICOM images of the adult cardiac and/or abdominal aorta.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Automatic 3D aortic lumen and wall-to-wall segmentation with 22 labeled aortic anatomical landmarks, delivered as DICOM result files viewable by DICOM-compliant systems.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Adult cardiac or abdominal aortic CTA review, measurement, and procedure-planning workflows.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Trained professionals responsible for patient management; results are used with other patient information and the standard of care.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The indication is for adults and excludes patients with a pre-existing aortic device, bicuspid aortic valve anomaly, aortic dissection, aortic rupture, or abdominal metallic devices. Motion, occluded vessels, lack of contrast, artifacts, or landmarks outside the field of view can prevent annotation or affect output. The device does not alter original input data and does not provide a diagnosis.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K243158 FDA evidence is a retrospective manufacturer-submitted regulatory validation. Segmentation results come from 170 adult aortic CTA studies; landmarking required 29 supplemental studies after field-of-view and artifact exclusions, so the exact unique total across endpoints is not inferred. No independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K243158 FDA evidence is a retrospective manufacturer-submitted regulatory validation. Segmentation results come from 170 adult aortic CTA studies; landmarking required 29 supplemental studies after field-of-view and artifact exclusions, so the exact unique total across endpoints is not inferred. No independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Aortic lumen segmentation mean Dice

0.88 Dice coefficient

  • EndpointMean aortic lumen segmentation Dice score versus ground truth
  • Population170 adult aortic CTA studies meeting the FDA-described inclusion and exclusion criteria
  • Tested versionTeraRecon Aorta.CT (1.1.0) configuration described in K243158

Aorta wall-to-wall segmentation mean Dice

0.9 Dice coefficient

  • EndpointMean aorta wall-to-wall segmentation Dice score versus ground truth
  • Population170 adult aortic CTA studies meeting the FDA-described inclusion and exclusion criteria
  • Tested versionTeraRecon Aorta.CT (1.1.0) configuration described in K243158

K243158 aortic segmentation regulatory validation

  • DesignRetrospective cohort validation comparing automated aortic lumen and wall-to-wall segmentation with established ground truth.
  • Population170 adults with cardiac and/or abdominal aortic CTA, enriched for aortic dilation/aneurysm and/or aortic valve disease; at least half of ground-truth data came from US patients across three US geographic regions.
  • Scopeexact submission
  • Tested versionTeraRecon Aorta.CT (1.1.0) configuration described in K243158
  • Samplen=170
  • IndependenceSponsor or vendor study

K243158

Final scanner distribution was 77 Siemens, 33 GE, 35 Philips, and 25 Canon. Manufacturer-submitted FDA evidence, not an independent clinical-outcome study.

K243158 aortic landmarking regulatory validation

  • DesignRetrospective regulatory validation of 22 aortic landmark outputs against ground-truth annotations using vessel identification, distance, and bifurcation-area criteria.
  • PopulationThe landmarking evaluation began with the 170-study cohort and added 29 supplemental studies because 40-45% of landmarks were outside the field of view or affected by artifacts; annotatable landmarks averaged 73 per target with a minimum of 63.
  • Scopeexact submission
  • Tested versionTeraRecon Aorta.CT (1.1.0) configuration described in K243158
  • IndependenceSponsor or vendor study

K243158

All 22 landmarks passed the stated 80% case-wise criterion and all exact 95% confidence-interval lower bounds were at least 70%. No exact unique total across this context and the segmentation set is inferred.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-submission FDA recall query returned no native recall record for K243158. This is not a comprehensive safety clearance and does not exclude family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Contrast CT angiography DICOM images of the adult cardiac and/or abdominal aorta.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K243158: TeraRecon Aorta.CT (1.1.0)

  2. Routing

    Source context, not route validation: The exact submission accepts CTA DICOM and returns DICOM result files for viewing by DICOM-compliant systems; local routing, viewer behavior, identifiers, and report ingestion require site acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K243158: TeraRecon Aorta.CT (1.1.0)

  3. AI processing

    Source context, not route validation: The exact submission is a containerized application that can run on off-the-shelf hardware or on a cloud platform; the reviewed sources do not establish the current site-specific hosting, storage, retention, availability, or service-level arrangement.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K243158: TeraRecon Aorta.CT (1.1.0)

  4. Returned objects

    Source context, not route validation: Automatic 3D aortic lumen and wall-to-wall segmentation with 22 labeled aortic anatomical landmarks, delivered as DICOM result files viewable by DICOM-compliant systems.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K243158: TeraRecon Aorta.CT (1.1.0)

  5. Viewer/worklist/report

    Unresolved route: Automatic 3D aortic lumen and wall-to-wall segmentation with 22 labeled aortic anatomical landmarks, delivered as DICOM result files viewable by DICOM-compliant systems.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K243158: TeraRecon Aorta.CT (1.1.0)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact submission is a containerized application that can run on off-the-shelf hardware or on a cloud platform; the reviewed sources do not establish the current site-specific hosting, storage, retention, availability, or service-level arrangement.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The exact submission accepts CTA DICOM and returns DICOM result files for viewing by DICOM-compliant systems; local routing, viewer behavior, identifiers, and report ingestion require site acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Security
TeraRecon announces it has been recognized as an ISO 27001:2022 certified company, maintaining an information security management system with documented processes for managing sensitive company information, HR processes, and IT systems; the announcement names TeraRecon's Intuition product and Eureka Clinical AI platform.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; the certificate was not read (a certificate PDF is hosted on the same owning domain). Applicant name variants (TeraRecon Inc. with punctuation/case variants) are bridged via the identical distinctive name. Exact-release scope is not established.

Monitoring
Monitor adult CTA eligibility, contrast and field-of-view adequacy, motion or artifact-related failures, segmentation and landmark review, DICOM result delivery, failed or repeated analyses, reader overrides, downtime, updates, complaints, and exact-submission recalls.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.

Current Aorta.CT regulatory workflow

TeraRecon's current regulatory page describes Aorta.CT as automatic 3D aortic segmentation and landmarking from contrast CT angiography DICOM, with DICOM result files usable by DICOM-compliant systems and no alteration of original data or diagnosis. This is current product-family context, not exact-version performance evidence.

product family · checked 2026-09-07

Containerized DICOM result workflow

The exact FDA submission describes a containerized application on off-the-shelf hardware or a cloud platform and DICOM result output; confirm container runtime, compute, storage, routing, and upgrade behavior during local qualification.

exact submission · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243158
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-01-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor regulatory page, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or exact contract unit for K243158 was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "TeraRecon Aorta.CT reimbursement"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The FDA indication requires trained professionals and understanding of capabilities and limitations, but no exact-version curriculum, competency assessment, or support terms were established.

9 sources - 3 history items

Source ledger

  1. FDA 510(k) K243158: TeraRecon Aorta.CT (1.1.0)

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. TeraRecon Aorta.CT (1.1.0) model card (K243158)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. TeraRecon regulatory descriptions: Aorta.CT

    TeraRecon - Accessed 2026-09-07

    Scope: productFamily, clinicalUse, output, implementationCapabilities, limitations

  8. openFDA exact recall query for K243158

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

  9. TeraRecon: ISO 27001:2022 Certification Announcement

    TeraRecon - Published 2023-05-30 - Accessed 2026-10-27

    Scope: security

Research history

  1. K243158 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K251656

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-09-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history